Neuropsychiatric adverse effects following switch to vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: early experience from a regional centre. (PubMed, J Cyst Fibros) - Sep 20, 2026 - "Vanzacaftor-tezacaftor-deutivacaftor (VTD) is the newest triple-combination CFTR modulator, licensed as an alternative to elexacaftor-tezacaftor-ivacaftor (ETI)...Three had no prior psychiatric history; one had pre-existing depression on long-term sertraline that markedly worsened...These findings highlight the need for early mental health screening after VTD initiation and a low threshold for psychiatric review. All cases have been reported to the MHRA Yellow Card scheme."
Adverse events • Journal • CNS Disorders • Cystic Fibrosis • Depression • Genetic Disorders • Immunology • Psychiatry • Pulmonary Disease • Respiratory Diseases • Suicidal Ideation
|
|
A P Sawant; D G Peckham; H Saumtally; I J Clifton; N Shaw
|